Agilon Health stock falls 2.63 percent after strong Q2

Agilon Health stock fell 2.63 percent to USD 84.56 on the NYSE on September 23, 2026, extending the distance to its 52-week high of USD 133.04 to 36.44 percent. The move came as investors weighed a sharp Q2 improvement against the medical cost risks that still shape the turnaround.

Q2 results change the picture

Agilon Health reported Q2 2026 revenue of USD 1.494743 billion, up 7 percent from USD 1.39 billion in Q2 2025, according to MarketWatch. Gross profit reached USD 107 million after a gross loss of USD 52 million in the prior-year quarter.

Net income was USD 18 million in Q2 2026, compared with a USD 104 million net loss in Q2 2025. That swing gives the stock a clearer operating benchmark than revenue growth alone, because profitability and medical cost control are central to the company transformation.

Guidance points to profitability

At the September 14, 2026 Jefferies conference, management raised full-year 2026 adjusted EBITDA guidance to USD 75 million to USD 95 million, according to Investing.com. The same update cited USD 257 million in cash at the end of Q2 and a year-end cash expectation of at least USD 125 million.

The market has already received a more bullish analyst signal. Yahoo Finance reported on September 15, 2026, that Bernstein SocGen Group upgraded Agilon Health to Outperform from Market Perform and raised its price target from USD 86 to USD 125.

Stock remains below its yearly high

Agilon Health stock was trading at USD 84.56 on September 23, 2026, with a daily change of minus 2.63 percent. Its 52-week range was USD 7.48 to USD 133.04, while its market capitalization stood at USD 1.410780944 billion.